Please Note: This trial is no longer enrolling new participants
A phase II trial of sitravatinib plus nivolumab in patients with metastatic clear cell renal cell carcinoma who progressed on prior treatment Acronym: SNAPI (Sitravatinib and Nivolumab After Prior Immunotherapy)
| Protocol No. | CTO-SNAPI2021-0057 | Scope | National |
|---|---|---|---|
| Principal Investigator | Nabil Adra | Treatment Type | Treatment |
| Age Group | Adult | Phase | Phase II |
